Markedly accelerated catabolism of apolipoprotein A-II (ApoA-II) and high density lipoproteins containing ApoA-II in classic lecithin: cholesterol acyltransferase deficiency and fish-eye disease.
Classic (complete) lecithin:cholesterol acyltransferase (LCAT) deficiency and Fish-eye disease (partial LCAT deficiency) are genetic syndromes associated with markedly decreased plasma levels of high density lipoprotein (HDL) cholesterol but not with an increased risk of atherosclerotic cardiovascular disease. We investigated the metabolism of the HDL apolipoproteins (apo) apoA-I and apoA-II in a total of five patients with LCAT deficiency, one with classic LCAT deficiency and four with Fish-eye disease. Plasma levels of apoA-II were decreased to a proportionately greater extent (23% of normal) than apoA-I (30% of normal). In addition, plasma concentrations of HDL particles containing both apoA-I and apoA-II (LpA-I:A-II) were much lower (18% of normal) than those of particles containing only apoA-I (LpA-I) (51% of normal). The metabolic basis for the low levels of apoA-II and LpA-I:A-II was investigated in all five patients using both exogenous radiotracer and endogenous stable isotope labeling techniques. The mean plasma residence time of apoA-I was decreased at 2.08 +/- 0.27 d (controls 4.74 +/- 0.65 days); however, the residence time of apoA-II was even shorter at 1.66 +/- 0.24 d (controls 5.25 +/- 0.61 d). In addition, the catabolism of apoA-I in LpA-I:A-II was substantially faster than that of apoA-I in LpA-I. In summary, genetic syndromes of either complete or partial LCAT deficiency result in low levels of HDL through preferential hypercatabolism of apoA-II and HDL particles containing apoA-II. Because LpA-I has been proposed to be more protective than LpA-I:A-II against atherosclerosis, this selective effect on the metabolism of LpA-I:A-II may provide a potential explanation why patients with classic LCAT deficiency and Fish-eye disease are not at increased risk for premature atherosclerosis despite markedly decreased levels of HDL cholesterol and apoA-I.
Rader
D J
DJ
Molecular Disease Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 20892.
Ikewaki
K
K
Duverger
N
N
Schmidt
H
H
Pritchard
H
H
Frohlich
J
J
Clerc
M
M
Dumon
M F
MF
Fairwell
T
T
Zech
L
L
D000328:Adult; D000368:Aged; D016633:Apolipoprotein A-II / Q000032:analysis / Q000378:metabolism*; D001053:Apolipoproteins / Q000032:analysis / Q000378:metabolism*; D003404:Creatinine / Q000097:blood; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes; D007863:Lecithin Cholesterol Acyltransferase Deficiency / Q000097:blood / Q000378:metabolism* / Q000652:urine; D008075:Lipoproteins, HDL / Q000097:blood*; D008297:Male; D008875:Middle Aged; D007862:Phosphatidylcholine-Sterol O-Acyltransferase / Q000235:genetics; D017354:Point Mutation; D011507:Proteinuria; D011865:Radioisotope Dilution Technique; D012016:Reference Values; D014316:Tritium
D016633:Apolipoprotein A-II; D001053:Apolipoproteins; D007457:Iodine Radioisotopes; D008075:Lipoproteins, HDL; D014316:Tritium; D003404:Creatinine; D007862:Phosphatidylcholine-Sterol O-Acyltransferase